Details of the Drug

General Information of Drug (ID: DMCT31R)

Drug Name
Carbinoxamine
Synonyms
Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Common cold CA00 Approved [1]
Seasonal allergic rhinitis CA08.01 Approved [1]
Urticaria EB00-EB05 Approved [1]
Vasomotor/allergic rhinitis CA08 Approved [2]
Pruritus EC90 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antihistamines
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 290.79
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [4]
Chemical Identifiers
Formula
C16H19ClN2O
IUPAC Name
2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
Canonical SMILES
CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
InChI
InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
InChIKey
OJFSXZCBGQGRNV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2564
ChEBI ID
CHEBI:3398
CAS Number
486-16-8
DrugBank ID
DB00748
TTD ID
D00FGV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Carbinoxamine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [7]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [8]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [7]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [7]
Coadministration of a Drug Treating the Disease Different from Carbinoxamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Memantine. Alzheimer disease [8A20] [7]
Rivastigmine DMG629M Moderate Antagonize the effect of Carbinoxamine when combined with Rivastigmine. Alzheimer disease [8A20] [9]
Donepezil DMIYG7Z Moderate Antagonize the effect of Carbinoxamine when combined with Donepezil. Alzheimer disease [8A20] [9]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [7]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Cariprazine. Bipolar disorder [6A60] [7]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Carbinoxamine and Loperamide. Bowel habit change [ME05] [10]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Carbinoxamine when combined with Acetylcholine. Cataract [9B10] [11]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [12]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [12]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [12]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Carbinoxamine and Olopatadine. Conjunctiva disorder [9A60] [13]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Carbinoxamine and Ethanol. Cystitis [GC00] [13]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Cyclobenzaprine. Depression [6A70-6A7Z] [7]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Carbinoxamine and Isocarboxazid. Depression [6A70-6A7Z] [14]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Carbinoxamine and Tranylcypromine. Depression [6A70-6A7Z] [14]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Carbinoxamine and OPC-34712. Depression [6A70-6A7Z] [7]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Carbinoxamine and Phenelzine. Depression [6A70-6A7Z] [14]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Clomipramine. Depression [6A70-6A7Z] [7]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Doxepin. Depression [6A70-6A7Z] [7]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Maprotiline. Depression [6A70-6A7Z] [7]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Carbinoxamine and Esketamine. Depression [6A70-6A7Z] [15]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Mepenzolate. Digestive system disease [DE2Z] [7]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Oxybutynine. Discovery agent [N.A.] [7]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Carbinoxamine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [16]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Diphenhydramine. Episodic vestibular syndrome [AB31] [7]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Solifenacin. Functional bladder disorder [GC50] [7]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Tolterodine. Functional bladder disorder [GC50] [7]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Propantheline. Gastric ulcer [DA60] [7]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Carbinoxamine when combined with Pilocarpine. Glaucoma [9C61] [11]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Carbinoxamine and Procarbazine. Hodgkin lymphoma [2B30] [14]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Carbinoxamine and Potassium chloride. Hypo-kalaemia [5C77] [17]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [7]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Amantadine. Influenza [1E30-1E32] [18]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Propiomazine. Insomnia [7A00-7A0Z] [7]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Carbinoxamine and ITI-007. Insomnia [7A00-7A0Z] [7]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Clidinium. Irritable bowel syndrome [DD91] [7]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Dicyclomine. Irritable bowel syndrome [DD91] [7]
Physostigmine DM2N0TO Moderate Antagonize the effect of Carbinoxamine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [9]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Carbinoxamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [19]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Carbinoxamine and Lasmiditan. Migraine [8A80] [20]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Carbinoxamine and Flibanserin. Mood disorder [6A60-6E23] [21]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Carbinoxamine and Thalidomide. Multiple myeloma [2A83] [22]
Ozanimod DMT6AM2 Moderate Additive CNS depression effects by the combination of Carbinoxamine and Ozanimod. Multiple sclerosis [8A40] [14]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Phenindamine. Nasopharyngitis [CA00] [7]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Dimenhydrinate. Nausea/vomiting [MD90] [7]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Promethazine. Nausea/vomiting [MD90] [7]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Cyclizine. Nausea/vomiting [MD90] [7]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Carbinoxamine and Apraclonidine. Optic nerve disorder [9C40] [23]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Flavoxate. Pain [MG30-MG3Z] [7]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Biperiden. Parkinsonism [8A00] [7]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Orphenadrine. Parkinsonism [8A00] [7]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Methylscopolamine. Peptic ulcer [DA61] [7]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Levomepromazine. Psychotic disorder [6A20-6A25] [7]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Quetiapine. Schizophrenia [6A20] [7]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Mesoridazine. Schizophrenia [6A20] [7]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Aripiprazole. Schizophrenia [6A20] [7]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Iloperidone. Schizophrenia [6A20] [7]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Paliperidone. Schizophrenia [6A20] [7]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Perphenazine. Schizophrenia [6A20] [7]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Molindone. Schizophrenia [6A20] [7]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Thiothixene. Schizophrenia [6A20] [7]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Trifluoperazine. Schizophrenia [6A20] [7]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Asenapine. Schizophrenia [6A20] [7]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Carbinoxamine and Pimozide. Schizophrenia [6A20] [7]
⏷ Show the Full List of 67 DDI Information of This Drug

References

1 Carbinoxamine FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.
6 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
7 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
8 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
9 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
10 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
11 Multum Information Services, Inc. Expert Review Panel.
12 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
13 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
14 Canadian Pharmacists Association.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
17 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
18 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
19 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
20 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
21 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
22 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
23 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.